HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

<p class="MsoNormal">Featuring an interview with Dr Laura Huppert, including the following topics:</p> <ul> <li>General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00)</li> <li>Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44)</li> <li>Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30)</li> <li>Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13)</li> <li>Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25)</li> <li>CNS penetration and activity of ADCs in the treatment of breast cancer (22:27)</li> <li>Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24)</li> <li>Treatment options in the second line and b...